Epidemiological description and treatment of Crohn's disease patients
DOI:
https://doi.org/10.51481/amc.v55i4.814Keywords:
Crohn's disease, gastrointestinal fistula, colectomyAbstract
Background: Crohn's disease is a chronic granulomatous inflammatory entity that can affect the entire gastrointestinal tract. It is being diagnosed with increased frequency in our medium, and constitutes an important cause of morbimortality in affected patients. The objective of this study is to determine the disease's prevalence, its frequent clinical manifestations, the various treatments used and the clinical response to such treatments.
Methods: The medical records of all patients with a diagnosis of Crohns disease who were evaluated during 2009 at the Gastroenterology Department of a tertiary center, the ""Dr. Rafael A. Calderón Guardia"" Hospital, were reviewed.Results: Out of a total of 28 patients, only three cases were diagnosed in the 1990-2000 decade, while the remaining 25 cases were diagnosed between 2001 to 2009. Sixty percent of the diagnosed cases correspond to male patients. The population studied had an age distribution from 17 to 72 years, with an average and median age of 39 years. Eighty-two percent of the patients are receiving maintenance therapy with aminosalicylates, while 62% also uses AZA, 6-MP or MTX; 51% is on systemic steroid therapy and only seven patients received infliximab. Patients who required surgical treatment at some point amounted to 68%, and remission was achieved in 96% of patients.
Downloads
References
Baumgart D.The Diagnosis and Treatment of Crohn´s Disease and Ulcerative Colitis. Dtsch Arztebl Int 2009; 106: 123-33.
Freeman HJ. Long-term natural history of Crohn´s disease. World J Gastroenterol 2009; 15: 1315-1318.
Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J. Clin. Invest. 2007; 117:514-521.
Kozuch P, Hanauer SP. Treatment of inflammatory bowel disease: A review of medical therapy. World J Gastroenterol 2008; 14:354377.
Karlinger K, Gjörke T, Mak kö E, Mester A, Tarján Z. Epidemiology and pathogenesis of inflammatory bowel disease. Eur J Radiol. 2000; 35:154-167.
Carter MJ, Lobo AJ, Travis SPL. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53; 1-16.
Karlinger K, Gjörke T, Makö E, Mester A, Tarján Z. Epidemiology and pathogenesis of inflammatory bowel disease. Eur J Radiol. 2000; 35:154-167.
Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 2006; 12:4819-31.
Barreiro-de Acosta M, Domínguez-Muñoz JE, Núñez-Pardo de Vera MC, Lozano-León A, Lorenzo A, Peña S. Relationship between clinical features of Crohn´s disease and the risk of developing extraintestinal manifestations. Eur J Gastroenterol Hepatol. 2007; 19:73-8.
Repiso A, Alcántara M, Muñoz-Rosas C, Rodríguez-Merlo R, Pérez-Grueso MJ, Carrobles JM, Martínez-Potenciano JL. Extraintestinal manifestations of Crohn´s disease: prevalence and related factors. Rev Esp Enferm Dig. 2006; 98:510-7.
Jones J, Panaccione R. Biologic therapy in Crohn`s disease: state of the art. Curr Opin Gastroenterol 2008; 24:475-481.
Sohrabpour AA, Malekzadeh R, Keshavarzian A. Current therapeutic approaches in inflammatory bowel disease. Curr Pharm Des. 2010; 16:3668-83.
Burger D, Travis S. Conventional medical management of inflammatory bowel disease. Gastroenterology. 2011; 140:18271837.
Fascí Spurio F, Aratari A, Margagnoni G, Doddato MT, Papi C. Early treatment in Crohn›s disease: do we have enough evidence to reverse the therapeutic pyramid? J Gastrointestin Liver Dis. 2012; 21:67-73.
Farmer RG, Easley KA, Rankin GB. Clinical patterns, natural history, and progression of ulcerative colitis: a long-term followup of 1116 patients. Dig Dis Sci 1993; 38:1137-1146.
Travis SPL, Stange EF, Lémann M, Öresland T, Chowers Y, Forbes A et al. European evidence based consensus on the diagnosis and management of Crohn´s disease: current management. Gut 2006; 55 (Suppl I); i16-i35.
Baumgart DC. Treatment of inflammatory bowel disease: A review of medical therapy. World J Gastroenterol 2008; 14:354377.
Pearson DC, May GR, Fick GH, et al.: Azathioprine and 6-mercaptopurine in Crohn disease: a meta-analysis. Ann Intern Med 1995; 123:132-142.
Latella G, Cocco A, Angelucci E, Viscido A, Bacci S, Necozione S, Caprilli R. Clinical course of Crohn's disease first diagnosed at surgery for acute abdomen. Dig Liver Dis. 2009; 41:269-76.
D´Haens G, Daperno M. Advances in biologic therapy for ulcerative colitis and Crohn´s disease. Curr Gastroenterol Rep. 2006; 8:506-12.
Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. A shortterm study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337:1029-1035.
Topstad DR, Panaccione R, Heine JA, Johnson DR, MacLean AR, Buie WD. Infliximab for the treatment of fistulas in patients with Crohn´s disease. N Engl J Med 1999; 340:1398-1405.
Hoentjen F, van Bodegraven AA. Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World J Gastroenterol 2009; 15:2067-2073.
Downloads
Published
Versions
- 2013-10-21 (2)
- 2013-10-21 (1)
Issue
Section
License
Copyright (c) 2013 Acta Médica Costarricense
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)
